| Drug Name: | Thioridazine (50-52-2) |
|---|---|
| PubChem ID: | 5452 |
| SMILES: | CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC |
| InchiKey: | KLBQZWRITKRQQV-UHFFFAOYSA-N |
| Therapeutic Category: | Antipsychotic Agents, Central Nervous System Agents, Central Nervous System Depressants, Dopamine Agents, Dopamine Antagonists, Neurotransmitter Agents, Psychotropic Drugs, Tranquilizing Agents |
| Molecular Weight (dalton) | : | 370.587 |
| LogP | : | 5.8856 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 6.48 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Phenytoin (57-41-0) | Phenytoin Toxicity | Synergistic | Uncertain. Phenothiazines such as thioridazine are inhibitors of the cytochrome P450 isoenzyme CYP2D6 | Inhibition of phenytoin metabolism by other drugs used in epilepsy |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Akathisia | D(2) dopamine receptor (P14416) | Antipsychotic response (D2@ D3@ D4)@antipsychotic-induced tardive dyskinesia (D3)@antipsychotic-induced acute akathisia (D3). [ ADR Type 2 ] | Pharmacogenetics and antipsychotic drugs |
| Akathisia | D(3) dopamine receptor (P35462) | Antipsychotic response (D2@ D3@ D4)@antipsychotic-induced tardive dyskinesia (D3)@antipsychotic-induced acute akathisia (D3). [ ADR Type 2 ] | Pharmacogenetics and antipsychotic drugs |
| Akathisia | D(4) dopamine receptor (P21917) | Antipsychotic response (D2@ D3@ D4)@antipsychotic-induced tardive dyskinesia (D3)@antipsychotic-induced acute akathisia (D3). [ ADR Type 2 ] | Pharmacogenetics and antipsychotic drugs |
| Seizures | G protein-activated inward rectifier potassium channel (P48549) | Antipsychotic drugs also inhibited the cardiac-type GIRK1/4 heteromultimeric channels@underlies the side effect of seizures [ ADR Type 1 ] | Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes |
| Tachycardia | G protein-activated inward rectifier potassium channel (P48549) | In oocytes co-injected with GIRK1 and GIRK2 mRNAs@ application of thioridazine immediately caused a reduction of inward currents through the basally active GIRK channels@underlies the side effect of sinus tachycardia [ ADR Type 1 ] | Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes |
| Tardive Dyskinesia | D(2) dopamine receptor (P14416) | Antipsychotic response (D2@ D3@ D4)@antipsychotic-induced tardive dyskinesia (D3)@antipsychotic-induced acute akathisia (D3). [ ADR Type 2 ] | Pharmacogenetics and antipsychotic drugs |
| Tardive Dyskinesia | D(3) dopamine receptor (P35462) | Antipsychotic response (D2@ D3@ D4)@antipsychotic-induced tardive dyskinesia (D3)@antipsychotic-induced acute akathisia (D3). [ ADR Type 2 ] | Pharmacogenetics and antipsychotic drugs |
| Tardive Dyskinesia | D(4) dopamine receptor (P21917) | Antipsychotic response (D2@ D3@ D4)@antipsychotic-induced tardive dyskinesia (D3)@antipsychotic-induced acute akathisia (D3). [ ADR Type 2 ] | Pharmacogenetics and antipsychotic drugs |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category